Geron, Cambrex announce manufacturing arrangement for cancer vaccine Grnvac1

By Elaine Rigoli

Tampa, Fla., Feb. 13 - Geron Corp. and Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corp., announced Monday an agreement for the manufacture of Geron's Grnvac1 telomerase vaccine.

The agreement provides for the transfer of Geron's vaccine production process to Cambrex and the cGMP manufacture of Grnvac1 by Cambrex, according to a company release.

A therapeutic cancer vaccine, Grnvac1 showed no major treatment-related toxicities during its phase 1 and phase 2 clinical trials, the companies said. In addition, they stated that telomerase specific T-cell responses were generated in 19 of 20 subjects and vaccination was associated with an increase in PSA doubling time and clearance of prostate cancer cells from the patients' blood, indicative of potential clinical response.

The telomerase vaccine is currently in multiple phase 1 and phase 2 trials at Duke University, where different strategies to optimize vaccine performance are under evaluation.

Geron is a Menlo Park, Calif.-based biopharmaceutical company that develops various cancer drugs. Cambrex is an East Rutherford, N.J.-based life sciences company providing products and services for human therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.